Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VH4524184 first-in-human dose escalation study in healthy volunteers
NCT05631704Phase 1Completed
- Sponsor
- ViiV Healthcare
- Start
- Dec 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VH4524184 in human immunodeficiency virus infection (HIV) (19 cohorts), sponsored by ViiV Healthcare. Primary endpoints: Serious Adverse Events and Non-Serious Adverse Events at 6.5 weeks, Adverse Events by Severity at 6.5 weeks and 15 more. Started Dec 2022; status: completed.
02
Drugs
VH4524184
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05631704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05631704.